KITE-753 Clinical Trials (2026): 3 Studies for Relapsed and/or Refractory B-cell Lymphoma & Relapsed or Refractory Large B-cell Lymphoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
3 KITE-753 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Relapsed and/or Refractory B-cell Lymphoma & Relapsed or Refractory Large B-cell Lymphoma) and 1,797 total planned enrollment. 1 Phase 3 KITE-753 trial are listed. 3 KITE-753 clinical trials are actively recruiting at 14 U.S. sites across 11 states. Most recent activity: NCT05041309 (Dec 2040).
Where to Participate: All KITE-753 Trial Sites in the U.S. (14 sites across 11 states)
Every actively recruiting KITE-753trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | Banner MD Anderson Cancer Center | Gilbert85234 | NCT04989803 | Map |
| CA | City of Hope (City of Hope National Medical Center, City of Hope Medical Center) | Duarte91010 | NCT04989803 | Map |
| CA | Stanford Cancer Institute | Stanford94305 | NCT04989803 | Map |
| CA | Stanford University | Stanford94305 | NCT07479797 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT04989803 | Map |
| GA | Northside Hospital | Atlanta30342 | NCT04989803 | Map |
| IL | Midwestern Regional Medical Center, Inc.City of Hope Chicago | Park Ridge60068 | NCT04989803 | Map |
| MD | University of MD, Greenebaum Comprehensive Cancer Center | Baltimore21201 | NCT04989803 | Map |
| NJ | Hackensack University Medical Center | Hackensack07601 | NCT04989803 | Map |
| NY | Columbia University Irving Medical Center | New York10032 | NCT04989803 | Map |
| NY | University of Rochester Medical Center | Rochester14642 | NCT04989803 | Map |
| OH | The Ohio State University Wexner Medical Center - James Cancer Hospital | Columbus43210 | NCT04989803 | Map |
| TX | The University of Texas, MD Anderson Cancer Center | Houston77030 | NCT04989803 | Map |
| VA | Virginia Oncology Associates | Norfolk23502 | NCT04989803 | Map |
KITE-753 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | enrolling by invitation | Total |
|---|---|---|---|
| P1/P2 | 1 | 1 | |
| P3 | 1 | 1 | |
| N/A | 1 | 1 |
Recruiting KITE-753 clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05041309 | Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells | — | Solid and Hematological Malignancies | 1,000 | Dec 2021 |
| NCT07479797 | Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy | P3 | Relapsed or Refractory Large B-cell Lymphoma | 550 | May 2026 |
| NCT04989803 | PALISADES-1Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma | P1/P2 | Relapsed and/or Refractory B-cell Lymphoma | 247 | Oct 2021 |
KITE-753 clinical trials by indication
Relapsed or Refractory Large B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07479797 | — | P3 | recruiting | Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy |
Solid and Hematological Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05041309 | — | N/A | enrolling by invitation | Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells |
Relapsed and/or Refractory B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04989803 | PALISADES-1 | P1/P2 | recruiting | Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma |
All KITE-753 trials (3)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05041309 | Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells | — | enrolling by invitation | 1,000 | Kite, A Gilead Company | Dec 2021 | |
| NCT07479797 | Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy | P3 | recruiting | 550 | Kite, A Gilead Company | May 2026 | |
| NCT04989803 | PALISADES-1 | Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma | P1/P2 | recruiting | 247 | Kite, A Gilead Company | Oct 2021 |
KITE-753 clinical trials: frequently asked questions
- How many KITE-753 clinical trials are there?
- 3 KITE-753 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants.
- Are KITE-753 clinical trials recruiting in 2026?
- Yes — 3 KITE-753 trials are actively recruiting in 2026, with 14 U.S. sites across 11 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is KITE-753 being studied for?
- KITE-753 is being studied for Relapsed and/or Refractory B-cell Lymphoma, Relapsed or Refractory Large B-cell Lymphoma, Solid and Hematological Malignancies. The trials are grouped by indication on this page.
- What phase is KITE-753 in?
- KITE-753 clinical trials span 1 Phase 3. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors KITE-753 clinical trials?
- The lead sponsor across the most KITE-753 trials is Kite, A Gilead Company. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming KITE-753as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: